Literature DB >> 11291026

The neuropsychiatry of pathologic affect: an approach to evaluation and treatment.

D B Arciniegas1, J Topkoff.   

Abstract

The ability to skillfully regulate the internal experience and outward expression of emotion is among the most complex and recently acquired functions of the human brain. When the capacity for emotional regulation is compromised by disease or injury the impact on individuals and their families may be considerable, both with regard to psychological well-being and social and occupational function. This article describes first a framework for the description, evaluation, and treatment of affective dysregulation. We review the literature regarding disorders of affective regulation, and in particular affective lability. Although disorders of affect as they occur in common neuropsychiatric disorders (eg, stroke, multiple sclerosis, traumatic brain injury, and so on) are the focus of this article, the review incorporates information from the study of patients with primary psychiatric disorders and hence the discussion herein may also be relevant to the understanding and treatment of affective lability in these conditions. An overview of the neurobiology that appears most relevant to understanding such problems is presented, along with several specific methods that appear to be useful in the evaluation of patients with affective lability. Finally, we review the literature regarding the treatment of disorders of affect and offer some practical suggestions for the treatment of patients with these problems. Copyright 2000 Copyright by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11291026     DOI: 10.1053/scnp.2000.9554

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  12 in total

1.  Pseudobulbar affect: prevalence and quality of life impact in movement disorders.

Authors:  Roy E Strowd; Michael S Cartwright; Michael S Okun; Ihtsham Haq; Mustafa S Siddiqui
Journal:  J Neurol       Date:  2010-04-08       Impact factor: 4.849

2.  Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

Authors:  Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

Review 3.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

5.  Neuroanatomy of pseudobulbar affect : a quantitative MRI study in multiple sclerosis.

Authors:  Omar Ghaffar; Laury Chamelian; Anthony Feinstein
Journal:  J Neurol       Date:  2008-02-26       Impact factor: 4.849

Review 6.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

7.  Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2013-06

8.  Posterior Fossa Lesion Load and Pathological Laughing and Crying in Multiple Sclerosis.

Authors:  Jacqueline A Luhoway; Manas Sharma; Suresh Menon; Heather Rosehart; Sarah A Morrow
Journal:  Int J MS Care       Date:  2019 May-Jun

9.  Pharmacologic management of anxiety and affective lability during recovery from Guillain-Barré syndrome: some preliminary observations.

Authors:  Kristin Brousseau; David Arciniegas; Susie Harris
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

10.  Psychiatric comorbidity and quality of life in patients with post-stroke emotional incontinence.

Authors:  Dong-Ho Choi; Bo-Ok Jeong; Hee-Ju Kang; Sung-Wan Kim; Jae-Min Kim; Il-Seon Shin; Joon-Tae Kim; Man-Seok Park; Ki-Hyun Cho; Jin-Sang Yoon
Journal:  Psychiatry Investig       Date:  2013-10-16       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.